{"gene":"NR1I2","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1998,"finding":"SXR (NR1I2) was identified as a novel nuclear receptor that activates transcription in response to a diversity of natural and synthetic steroid and xenobiotic compounds. It forms a heterodimer with RXR that binds to and induces transcription from response elements present in steroid-inducible cytochrome P-450 genes (CYP3A). SXR is expressed in liver and intestine, the same tissues where these catabolic enzymes are expressed.","method":"Receptor cloning, transactivation assays, heterodimer binding/RXR co-transfection, tissue expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — original cloning paper with in vitro transactivation, heterodimer reconstitution, and DNA binding; foundational work replicated extensively","pmids":["9784494"],"is_preprint":false},{"year":1998,"finding":"BXR (an NR1I2 ortholog/related receptor) heterodimerizes with RXR and binds high-affinity DNA sites composed of a variant thyroid hormone response element. Alkyl esters of amino and hydroxy benzoic acids (benzoates) were identified as bona fide BXR ligands by in vitro cofactor association studies and competitive radiolabeled compound binding, establishing benzoates as a new molecular class of nuclear receptor ligand.","method":"Receptor cloning, in vitro ligand binding (radiolabeled compound displacement), cofactor association studies, mass spectrometry, 1H NMR, transactivation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods including radiolabeled binding, NMR, MS, and functional transactivation in single study","pmids":["9573044"],"is_preprint":false},{"year":2000,"finding":"Targeted disruption of mouse PXR (NR1I2) abolishes induction of CYP3A by prototypic inducers dexamethasone and pregnenolone-16α-carbonitrile (PCN), establishing PXR as the necessary mediator of CYP3A induction. Transgenic mice expressing an activated form of human SXR showed constitutive upregulation of CYP3A gene expression and enhanced protection against toxic xenobiotic compounds. The species origin of the receptor (not promoter structure) dictates species-specific CYP3A inducibility.","method":"PXR knockout mice, transgenic mice expressing activated SXR, CYP3A gene expression analysis, xenobiotic toxicity assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and transgenic gain-of-function in vivo, replicated across labs","pmids":["10935643"],"is_preprint":false},{"year":2000,"finding":"SXR/PXR can regulate CYP2B genes (not only CYP3A) via adaptive recognition of the phenobarbital response element (PBRE) in cultured cells and transgenic mice, revealing cross-regulation of CYP gene families. Reciprocally, orphan receptor CAR activates CYP3A through SXR/PXR response elements, establishing a metabolic safety net of overlapping xenobiotic receptor function.","method":"Transactivation assays in cultured cells, transgenic mouse studies, reporter gene assays with CYP2B PBRE and CYP3A XREM","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-based and in vivo transgenic experiments confirming cross-regulation; replicated concept","pmids":["11114890"],"is_preprint":false},{"year":2001,"finding":"SXR/PXR directly regulates MDR1 gene expression (encoding P-glycoprotein/ABCB1), coordinating both drug catabolism (CYP3A4) and drug efflux. Paclitaxel activated SXR and enhanced P-glycoprotein-mediated drug clearance, while docetaxel did not activate SXR. Docetaxel's inactivity was linked to its inability to displace transcriptional corepressors from SXR. ET-743 suppressed MDR1 transcription by acting as an SXR inhibitor.","method":"Reporter gene assays, RT-PCR for MDR1/CYP3A4 expression, corepressor displacement assays, pharmacokinetic studies","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic demonstration of MDR1 as SXR target with corepressor displacement mechanism; multiple orthogonal methods","pmids":["11329060"],"is_preprint":false},{"year":2001,"finding":"Human SXR and rodent PXR function as bile acid receptors; the secondary bile acid lithocholic acid (LCA) is a metabolic substrate for CYP3A hydroxylation and activates SXR/PXR. Using PXR knockout and SXR transgenic animals, SXR/PXR activation was shown to be necessary and sufficient to induce CYP3A enzymes and confer resistance to LCA hepatotoxicity, as well as to other xenotoxicants.","method":"PXR knockout mice, transgenic mice, LCA toxicity assays, CYP3A induction assays, cell-based transactivation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with both KO and transgenic overexpression; multiple ligands and phenotypic readouts","pmids":["11248086"],"is_preprint":false},{"year":2002,"finding":"Comparative pharmacological profiling of NR1I subfamily members identified three distinct receptor classes: PXRs (activated by broad range of xenobiotics and steroids), CARs (high basal activity, generally repressed), and BXRs (selectively activated by benzoate analogs). PXRs possess a unique H1-3 insert (stretch of amino acids between helices 1 and 3 absent in CARs and BXRs) that modeling suggests expands the ligand binding pocket by facilitating unwinding of helices 6 and 7, explaining PXR promiscuity.","method":"Ligand activation assays of LBD fusion proteins across species, structural modeling, sequence analysis","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — systematic pharmacological profiling with structural modeling; modeling is computational but supported by functional ligand data","pmids":["11981033"],"is_preprint":false},{"year":2003,"finding":"Vitamin K2 (menaquinone) binds to and activates the orphan nuclear receptor SXR/PXR and induces expression of the SXR target gene CYP3A4, identifying it as a bona fide SXR ligand. Vitamin K2 treatment increased mRNA levels for osteoblast markers (bone alkaline phosphatase, osteoprotegerin, osteopontin, matrix Gla protein) in osteosarcoma cells. Vitamin K2 could induce bone markers in primary osteocytes from wild-type but not PXR-deficient mice, establishing SXR as a mediator of bone homeostasis.","method":"Ligand binding assays, CYP3A4 reporter assays, RT-PCR, primary osteocyte cultures from PXR knockout mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — ligand binding, reporter assay, and PXR-KO genetic validation in primary cells; multiple orthogonal methods","pmids":["12920130"],"is_preprint":false},{"year":2004,"finding":"PXR (NR1I2) is expressed in many tissues beyond liver and intestine, including human bone marrow and select regions of human brain. Multiple alternatively spliced PXR isoforms (PXR.2 lacking 37 aa from LBD, PXR.3 lacking 41 aa from LBD) were identified. Neurosteroids allopregnanolone and pregnanolone activated PXR and induced CYP3A4-luciferase reporter transcription. Nicotine was identified as an efficacious PXR activator inducing CYP3A4 transcription.","method":"RT-PCR across 36 human tissues, CYP3A4-luciferase reporter assays, quantitative mRNA analysis in human liver","journal":"Toxicology and applied pharmacology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — cell-based transactivation assays for novel ligands; tissue expression by RT-PCR; single lab, multiple methods","pmids":["15364541"],"is_preprint":false},{"year":2004,"finding":"All four tocotrienols (but not tocopherols) specifically bind to and activate SXR/PXR. Tocotrienols show tissue-specific induction of SXR target genes: they upregulate CYP3A4 but not UGT1A1 or MDR1 in primary hepatocytes, whereas in intestinal LS180 cells they induce MDR1 and UGT1A1 but not CYP3A4. Unliganded SXR interacts with NCoR (nuclear receptor corepressor), and this interaction is only partially disrupted by tocotrienols; NCoR is expressed at higher levels in LS180 cells, contributing to tissue-specific gene regulation.","method":"Ligand binding assays, reporter gene assays, RT-PCR in primary hepatocytes and LS180 cells, co-immunoprecipitation of SXR-NCoR, dominant-negative NCoR overexpression","journal":"Drug metabolism and disposition: the biological fate of chemicals","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ligand binding, protein-protein interaction (co-IP), functional reporter assays with dominant-negative rescue; single lab, multiple orthogonal methods","pmids":["15269186"],"is_preprint":false},{"year":2009,"finding":"Activation of SXR/PXR in p53 wild-type breast cancer cells (MCF-7, ZR-75-1) inhibited proliferation by inducing G1/S cell cycle arrest and apoptosis. This was mechanistically dependent on SXR-induced upregulation of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production, leading to p53 stabilization and upregulation of p21, PUMA, and BAX. siRNA knockdown of SXR blocked iNOS induction; p53 knockdown blocked p21 and BAX upregulation.","method":"Cell proliferation assays, FACS cell cycle analysis, RT-PCR, western blotting, siRNA knockdown of SXR and p53, iNOS inhibition","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with specific mechanistic phenotype; multiple pathway components validated; single lab","pmids":["19123943"],"is_preprint":false},{"year":2009,"finding":"PGC-1α overexpression upregulates PXR expression in mouse primary hepatocytes, and siRNA knockdown of PPARα attenuates PGC-1α-mediated induction of PXR mRNA, indicating PPARα mediates PGC-1α's effect on PXR transcription. SIRT1 interacts with PXR (by co-immunoprecipitation) and pyruvate/SIRT1 activation interferes with PXR-PGC-1α interaction in mammalian two-hybrid assays, inhibiting synergistic CYP3A11 induction.","method":"PGC-1α overexpression and siRNA knockdown in primary hepatocytes, mammalian two-hybrid assay, co-immunoprecipitation, RT-PCR","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and two-hybrid for protein-protein interaction, siRNA knockdown, functional gene expression; single lab, multiple methods","pmids":["21933665"],"is_preprint":false},{"year":2011,"finding":"Metformin suppresses PXR-mediated CYP3A4 expression in human hepatocytes. Mechanistically, metformin disrupts PXR's interaction with steroid receptor coactivator-1 (SRC1) in a two-hybrid assay independently of the PXR ligand binding pocket. Metformin suppressed Cyp3a11 mRNA in wild-type but not Pxr−/− mice. AMPK activation and SHP upregulation were not required for this effect.","method":"Reporter gene assays, qRT-PCR in human hepatocytes and Pxr−/− mice, mammalian two-hybrid assay for PXR-SRC1 interaction, AMPK inhibition studies","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (Pxr-KO mice) and biochemical (two-hybrid) validation across multiple systems; mechanism of coactivator disruption established","pmids":["21920351"],"is_preprint":false},{"year":2011,"finding":"In colon cancer cells, SN-38 (active metabolite of irinotecan) activates endogenous SXR/PXR, causing its translocation into the nucleus where it associates with RXR. ChIP demonstrated that endogenous SXR binds to the native CYP3A4 gene promoter upon activation. siRNA confirmed SXR involvement in CYP3A4 overexpression and identified CYP3A5 and MRP2 transporter as SXR target genes. SXR overexpression reduced cellular sensitivity to irinotecan.","method":"Immunofluorescence (nuclear translocation), ChIP, siRNA knockdown, RT-PCR, drug sensitivity assays","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP on native promoter, nuclear translocation imaging, siRNA knockdown; multiple orthogonal methods in a single study","pmids":["21733184"],"is_preprint":false},{"year":2013,"finding":"PXR ablation in mice inhibited high-fat diet-induced obesity, hepatic steatosis, and insulin resistance through increased oxygen consumption, increased mitochondrial β-oxidation, inhibition of hepatic lipogenesis and inflammation, and sensitization of insulin signaling. Mechanistically, PXR ablation was associated with inhibition of c-Jun N-terminal kinase (JNK) activation and downregulation of lipin-1, identified as a novel PXR target gene. PXR ablation in ob/ob mice also improved metabolic phenotype.","method":"PXR knockout mice on HFD and ob/ob background, oxygen consumption measurements, euglycemic clamp, RT-PCR, lipin-1 promoter/target gene analysis","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic mouse models with defined mechanistic pathway (JNK, lipin-1 as target); multiple metabolic phenotypic readouts","pmids":["23349477"],"is_preprint":false},{"year":2016,"finding":"PXR is modified by acetylation on lysine residues. Increased acetylation of PXR stimulates its increased SUMOylation to support active transcriptional suppression (a 'SUMO-acetyl switch'). Pharmacologic inhibition of lysine deacetylation with trichostatin A (TSA) alters PXR subcellular localization in cultured hepatocytes and profoundly impacts PXR transactivation capacity. PXR associates with the lysine deacetylating enzyme HDAC3 in a complex with SMRT corepressor.","method":"Mass spectrometry identification of acetylation sites, cell-based transactivation assays with TSA, immunofluorescence for subcellular localization, co-immunoprecipitation of PXR-HDAC3-SMRT complex, SUMOylation assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS identification of PTM, co-IP for protein complex, functional localization and transactivation data; single lab, multiple methods","pmids":["26883953"],"is_preprint":false},{"year":2020,"finding":"PXR was robustly downregulated in kidneys with acute kidney injury (AKI). PXR targeted Aldo-keto reductase family 1 member B7 (AKR1B7) to improve mitochondrial function, determined by luciferase reporter assays and genomic manipulation. Silencing PXR in rats enhanced cisplatin-induced AKI with severe mitochondrial abnormalities; activating PXR protected against AKI. The PXR/AKR1B7/mitochondrial metabolism axis was validated in ischemia/reperfusion AKI model.","method":"Luciferase reporter assays, genomic manipulation (PXR silencing and activation), proteomics, cisplatin and ischemia/reperfusion AKI models in rats, renal function assays","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vivo genetic models, reporter assays, proteomics; AKR1B7 identified as direct target by genomic and pharmacological approaches","pmids":["32404507"],"is_preprint":false},{"year":2020,"finding":"PXR functionally interacts with both NF-κB and AP-1 transcription factors to downregulate inflammation-induced expression of chemokine CXCL2 in mouse liver. Reporter assays with mutated Cxcl2 promoter showed that mutation of both NF-κB and AP-1 binding sites abolished PXR-dependent suppression; mutation of either alone only partially reduced it. PXR activation (PCN) suppressed neutrophil infiltration and plasma transaminase activity in CCl4-injured mice.","method":"In vivo mouse liver injury model, qRT-PCR, reporter assays with wild-type and NF-κB/AP-1 mutated Cxcl2 promoters, plasma transaminase assays, histology","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed promoter mutagenesis reporter assays and in vivo validation; single lab","pmids":["33076328"],"is_preprint":false},{"year":2021,"finding":"PXR activation impaired hepatic glucose metabolism by inhibiting the HNF4α–GLUT2 pathway. PXR agonists downregulated HNF4α and GLUT2 expression; PXR overexpression decreased and PXR silencing increased HNF4α/GLUT2. HNF4α recruits to the Slc2a2 (GLUT2) promoter, and PCN suppressed this recruitment. Liver-specific Hnf4α deletion and PCN treatment impaired glucose tolerance and hepatic glucose uptake in mice.","method":"HepG2 cells and mouse/human primary hepatocytes with PXR overexpression/silencing, ChIP for HNF4α at Slc2a2 promoter, luciferase reporter assays, liver-specific Hnf4α knockout mice, glucose tolerance tests","journal":"Acta pharmaceutica Sinica. B","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, promoter reporter assays, multiple genetic models (KO mice, siRNA) across human and mouse systems; mechanistic pathway established","pmids":["35646519"],"is_preprint":false},{"year":2016,"finding":"Human PXR (hPXR) interacts with mycobacterial cell wall lipids (particularly mycolic acids) via its promiscuous ligand binding domain, as shown in macrophage infection studies. hPXR augments M. tuberculosis survival inside host macrophages by promoting foamy macrophage formation and abrogating phagolysosomal fusion, inflammation, and apoptosis. Expression of hPXR in humanized transgenic mice promoted M. tuberculosis survival in vivo.","method":"Human monocyte-derived macrophages, hPXR-transgenic mice, phagolysosomal fusion assays, lipid ligand binding studies, infection survival assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ligand-binding domain interaction with mycolic acids, in vitro macrophage studies, and hPXR transgenic mouse in vivo validation; single lab","pmids":["27233963"],"is_preprint":false},{"year":2011,"finding":"Upon stimulation with lithocholic acid, PXR translocates from cytoplasm to the nucleus of OE19 adenocarcinoma cells, as demonstrated by immunofluorescence in cell line experiments.","method":"Immunohistochemistry and immunofluorescence in esophageal cell lines and tissue, PXR stimulation with lithocholic acid","journal":"BMC gastroenterology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single localization observation in cell line without functional consequence measured; single lab, single method","pmids":["21977915"],"is_preprint":false},{"year":2015,"finding":"In mouse hippocampal neurons, nonylphenol induced translocation of PXR immunofluorescence from cytoplasm to the nucleus. siRNA knockdown of Pxr reduced nonylphenol-induced caspase-3 activation and LDH release, demonstrating that PXR signaling contributes to nonylphenol-induced apoptosis and neurotoxicity.","method":"Primary mouse hippocampal cell cultures, immunofluorescence for nuclear translocation, siRNA knockdown, caspase-3 activity assay, LDH release assay","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA genetic knockdown with specific phenotypic readouts and localization imaging; single lab, multiple methods","pmids":["26643981"],"is_preprint":false},{"year":2016,"finding":"PXR transcript variant 1 (PXR1) interacts with p53, whereas PXR transcript variant 3 (PXR3) does not, establishing a differential protein-protein interaction profile of PXR isoforms. Variants PXR3 and PXR4 do not induce target gene expression upon agonist treatment, whereas PXR1 and PXR2 do. PXR1 and PXR4 mRNA are downregulated by methylation in cancerous tissue.","method":"Protein-protein interaction assays (PXR1 vs PXR3 with p53), reporter gene assays for target gene transactivation, methylation analysis","journal":"Acta pharmaceutica Sinica. B","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single-method protein interaction data for isoforms; functional differences established but limited mechanistic depth reported in abstract","pmids":["27709012"],"is_preprint":false},{"year":2007,"finding":"PXR activates a SREBP-independent lipogenic pathway by inducing expression of the free fatty acid uptake transporter CD36, PPARγ, and accessory lipogenic enzymes stearoyl-CoA desaturase-1 (SCD-1) and long-chain free fatty acid elongase (FAE) in a liver-specific manner. Promoter analysis established CD36 as a transcriptional target of PXR. PPARγ is also a direct transcriptional target of PXR.","method":"Promoter analysis/reporter assays, RT-PCR for target gene expression, liver-specific expression analysis","journal":"Molecular pharmaceutics","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — promoter analysis and gene expression data establishing CD36 and PPARγ as direct PXR targets; single lab","pmids":["18072748"],"is_preprint":false},{"year":2019,"finding":"Patchouli alcohol (PA) activates PXR (identified as a PXR agonist by hPXR transactivation assays and CYP3A4 expression/activity induction). PA-mediated PXR activation attenuated NF-κB activity and nuclear translocation. PXR knockdown abolished the anti-inflammatory effect of PA on NF-κB, demonstrating that the anti-inflammatory effect is PXR-dependent. In vivo, PA prevented DSS-induced colitis by regulating PXR/NF-κB signaling.","method":"hPXR transactivation assays, NF-κB luciferase assays, NF-κB nuclear translocation imaging, PXR knockdown, DSS colitis mouse model, pharmacological PXR inhibition","journal":"Journal of ethnopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown and pharmacological inhibition validate PXR-NF-κB mechanistic link; in vitro and in vivo; single lab","pmids":["31614203"],"is_preprint":false}],"current_model":"NR1I2/PXR/SXR is a ligand-activated nuclear receptor that heterodimerizes with RXRα, binds xenobiotic response elements in gene promoters, and functions as a broad-specificity sensor of steroids, bile acids, and xenobiotics to transcriptionally induce phase I (CYP3A4, CYP2B) and phase II drug-metabolizing enzymes and transporters (MDR1/P-gp, MRP2); it also regulates energy metabolism (lipogenesis via CD36/PPARγ, gluconeogenesis via HNF4α–GLUT2 pathway), bile acid detoxification (CYP3A-mediated LCA hydroxylation), bone homeostasis (via vitamin K2 signaling), and inflammation (by suppressing NF-κB and AP-1), with its transcriptional activity modulated by post-translational modifications including phosphorylation, acetylation (by HDAC3/SMRT complex), and SUMOylation, as well as coactivator (SRC1, PGC-1α) and corepressor (NCoR, SMRT) interactions."},"narrative":{"mechanistic_narrative":"NR1I2 (SXR/PXR) is a ligand-activated nuclear receptor that functions as a broad-specificity sensor of steroids, bile acids, and xenobiotics, heterodimerizing with RXR and binding response elements in target gene promoters to induce drug-metabolizing enzymes and transporters in liver and intestine [PMID:9784494, PMID:21733184]. Its defining role is xenobiotic detoxification: it is the necessary and sufficient mediator of CYP3A induction by prototypic inducers, conferring protection against toxic compounds in vivo [PMID:10935643], and it coordinately controls cross-regulated CYP families through the phenobarbital response element [PMID:11114890] as well as drug efflux via MDR1/P-glycoprotein and MRP2 to integrate catabolism with clearance [PMID:11329060, PMID:21733184]. PXR is endogenously activated by the secondary bile acid lithocholic acid, driving CYP3A-mediated hydroxylation that detoxifies bile acids [PMID:11248086], and its unusually large, flexible ligand-binding pocket—conferred by a unique H1-3 insert—accommodates an exceptionally diverse ligand set including vitamin K2, tocotrienols, neurosteroids, nicotine, and bacterial mycolic acids [PMID:11981033, PMID:12920130, PMID:15269186, PMID:15364541, PMID:27233963]. Beyond detoxification, NR1I2 regulates energy metabolism, promoting a SREBP-independent lipogenic program via CD36 and PPARγ [PMID:18072748], impairing hepatic glucose handling by suppressing the HNF4α–GLUT2 pathway [PMID:35646519], and driving diet-induced obesity and insulin resistance through JNK activation and lipin-1 induction [PMID:23349477]. It also suppresses inflammation by antagonizing NF-κB and AP-1 to downregulate chemokines such as CXCL2 [PMID:33076328, PMID:31614203], mediates vitamin K2-dependent bone homeostasis [PMID:12920130], and exhibits tissue-protective metabolic functions, as in the PXR/AKR1B7/mitochondrial axis in acute kidney injury [PMID:32404507]. Its transcriptional output is tuned by coactivators (SRC1, PGC-1α) and corepressors (NCoR, SMRT) and by post-translational modification, including an acetylation–SUMOylation switch executed in complex with HDAC3/SMRT [PMID:15269186, PMID:21933665, PMID:21920351, PMID:26883953].","teleology":[{"year":1998,"claim":"Established the existence and basic mechanism of NR1I2 as a xenobiotic-responsive nuclear receptor, answering whether a single receptor could couple diverse chemical sensing to CYP3A induction.","evidence":"Receptor cloning, RXR heterodimer reconstitution, transactivation and DNA-binding assays, tissue expression analysis","pmids":["9784494","9573044"],"confidence":"High","gaps":["Endogenous physiological ligands not yet defined","In vivo requirement not established by genetics","Structural basis of ligand promiscuity unknown"]},{"year":2000,"claim":"Genetic knockout and gain-of-function transgenics proved PXR is the necessary in vivo mediator of CYP3A induction and that receptor species origin dictates inducibility, moving the receptor from in vitro candidate to physiological detoxification sensor.","evidence":"Pxr knockout and activated-SXR transgenic mice, CYP3A expression and xenobiotic toxicity assays","pmids":["10935643"],"confidence":"High","gaps":["Endogenous activating ligands not yet identified","Scope of target gene network beyond CYP3A unknown"]},{"year":2000,"claim":"Showed NR1I2 cross-regulates CYP2B via the PBRE and shares response elements reciprocally with CAR, establishing a redundant xenobiotic-response safety net rather than a single-gene regulator.","evidence":"Transactivation and reporter assays, transgenic mice with CYP2B PBRE and CYP3A XREM","pmids":["11114890"],"confidence":"High","gaps":["Quantitative contribution of each receptor in vivo not resolved","Determinants of element selectivity unclear"]},{"year":2001,"claim":"Identified MDR1/P-glycoprotein as a direct PXR target and revealed corepressor displacement as the discriminator between activating and non-activating ligands, linking drug catabolism with efflux clearance.","evidence":"Reporter assays, RT-PCR, corepressor displacement assays, pharmacokinetics with paclitaxel/docetaxel/ET-743","pmids":["11329060"],"confidence":"High","gaps":["Identity of displaced corepressors not fully mapped here","Genome-wide transporter target set undefined"]},{"year":2001,"claim":"Demonstrated NR1I2 is a bile acid receptor and that LCA is both a ligand and a CYP3A substrate, establishing a feed-forward detoxification loop necessary and sufficient for LCA resistance.","evidence":"Pxr knockout and transgenic mice, LCA toxicity and CYP3A induction assays, cell-based transactivation","pmids":["11248086"],"confidence":"High","gaps":["Other endogenous bile acid ligands not exhaustively profiled","Quantitative flux of LCA clearance not measured"]},{"year":2002,"claim":"Comparative profiling across NR1I subfamily attributed PXR promiscuity to a unique H1-3 insert that enlarges the ligand-binding pocket, providing a structural rationale for broad ligand sensing.","evidence":"LBD fusion-protein activation assays across species, structural modeling, sequence analysis","pmids":["11981033"],"confidence":"Medium","gaps":["Pocket-expansion model is computational, not crystallographic","Helix unwinding mechanism not experimentally resolved"]},{"year":2003,"claim":"Identified vitamin K2 as a bona fide PXR ligand mediating osteoblast marker induction, extending NR1I2 function from detoxification into bone homeostasis.","evidence":"Ligand binding, CYP3A4 reporter assays, RT-PCR, primary osteocytes from Pxr-knockout mice","pmids":["12920130"],"confidence":"High","gaps":["Direct bone marker genes as PXR targets not promoter-mapped","In vivo skeletal phenotype of Pxr loss not addressed"]},{"year":2004,"claim":"Expanded the ligand repertoire (neurosteroids, nicotine, tocotrienols) and tissue distribution, and showed NCoR corepressor levels drive tissue-specific target gene selection, explaining context-dependent PXR output.","evidence":"RT-PCR across 36 tissues, CYP3A4-luciferase reporters, ligand binding, SXR-NCoR co-IP, dominant-negative NCoR","pmids":["15364541","15269186"],"confidence":"Medium","gaps":["Functional roles of alternatively spliced isoforms unclear","Mechanism of differential NCoR release by ligand not resolved"]},{"year":2007,"claim":"Defined a SREBP-independent lipogenic program controlled by PXR through direct induction of CD36 and PPARγ, establishing NR1I2 as a regulator of hepatic lipid metabolism.","evidence":"Promoter/reporter analysis, RT-PCR for CD36/PPARγ/SCD-1/FAE, liver-specific expression","pmids":["18072748"],"confidence":"Medium","gaps":["In vivo metabolic consequence not tested in this study","Promoter binding shown only for subset of targets"]},{"year":2009,"claim":"Connected NR1I2 to coactivator/coregulator energy-sensing networks (PGC-1α, PPARα, SIRT1) and to a p53/iNOS tumor-suppressive program, broadening its regulatory inputs and outputs.","evidence":"PGC-1α overexpression/siRNA, mammalian two-hybrid, co-IP, siRNA of SXR/p53, iNOS inhibition in breast cancer cells","pmids":["21933665","19123943"],"confidence":"Medium","gaps":["Direct vs indirect coregulator effects partly inferred","Cancer-cell-type specificity of p53/iNOS axis unclear"]},{"year":2011,"claim":"Demonstrated that NR1I2 activity is modulated by ligand-independent coactivator disruption (metformin–SRC1) and confirmed activation-dependent nuclear translocation and native-promoter binding, refining the activation mechanism.","evidence":"Two-hybrid PXR-SRC1, reporter/qRT-PCR in human hepatocytes and Pxr-KO mice, ChIP on native CYP3A4 promoter, nuclear-translocation imaging, drug sensitivity assays","pmids":["21920351","21733184","21977915","27709012"],"confidence":"High","gaps":["Structural basis of pocket-independent SRC1 disruption unknown","Isoform-specific interaction differences (PXR1 vs PXR3) carry low-confidence support"]},{"year":2013,"claim":"Linked NR1I2 to systemic metabolic disease, showing Pxr ablation protects against diet-induced obesity and insulin resistance via JNK and the novel target lipin-1.","evidence":"Pxr-KO mice on HFD and ob/ob backgrounds, oxygen consumption, euglycemic clamp, RT-PCR, lipin-1 analysis","pmids":["23349477"],"confidence":"High","gaps":["Tissue-specific contribution of PXR not dissected","Relationship between lipogenic CD36/PPARγ program and lipin-1 axis unresolved"]},{"year":2016,"claim":"Established post-translational control of NR1I2 through an acetylation–SUMOylation switch executed in an HDAC3/SMRT complex, and a host-pathogen role via mycolic acid binding, deepening regulatory and immunological mechanism.","evidence":"Mass spectrometry of acetylation sites, TSA transactivation assays, localization imaging, PXR-HDAC3-SMRT co-IP, SUMOylation assays; macrophage infection and hPXR-transgenic mice","pmids":["26883953","27233963"],"confidence":"Medium","gaps":["Enzymes writing/erasing the SUMO-acetyl switch only partly defined","Physiological triggers of the modification switch unknown"]},{"year":2020,"claim":"Identified tissue-protective and anti-inflammatory mechanisms, defining the PXR/AKR1B7/mitochondrial axis in kidney injury and direct NF-κB/AP-1 antagonism suppressing CXCL2.","evidence":"Luciferase reporters, PXR silencing/activation, proteomics, cisplatin/IR AKI rat models; Cxcl2 promoter mutagenesis and CCl4 liver injury mouse model","pmids":["32404507","33076328"],"confidence":"High","gaps":["Direct PXR binding to AKR1B7 promoter vs indirect regulation not fully resolved","Generality of anti-inflammatory mechanism across tissues unclear"]},{"year":2021,"claim":"Resolved the mechanism by which PXR impairs glucose metabolism, showing it suppresses HNF4α recruitment to the GLUT2 promoter, completing a metabolic regulatory picture.","evidence":"PXR overexpression/silencing in hepatocytes, ChIP for HNF4α at Slc2a2, reporter assays, liver-specific Hnf4α-KO mice, glucose tolerance tests","pmids":["35646519"],"confidence":"High","gaps":["Whether PXR directly represses HNF4α or competes for cofactors unresolved","Integration with insulin signaling pathway not fully mapped"]},{"year":null,"claim":"How the diverse ligand inputs, coregulator balance, and post-translational modification switch are integrated to select among detoxification, metabolic, anti-inflammatory, and tissue-protective transcriptional programs in a tissue-specific manner remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of program selection across tissues","Genome-wide direct target catalog not consolidated","Functional consequences of splice isoforms largely uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,3,13,18,23]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,13]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,7,9,19]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[17,24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13,15,21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[13,20,21]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[0,2,4,5]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,13,18]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[14,18,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,19,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,13]}],"complexes":["NR1I2-RXR heterodimer","HDAC3/SMRT corepressor complex"],"partners":["RXR","NCOR1","SMRT","SRC1","PPARGC1A","SIRT1","HDAC3","TP53"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75469","full_name":"Nuclear receptor subfamily 1 group I member 2","aliases":["Orphan nuclear receptor PAR1","Orphan nuclear receptor PXR","Pregnane X receptor","Steroid and xenobiotic receptor","SXR"],"length_aa":434,"mass_kda":49.8,"function":"Nuclear receptor that acts as a transcription factor regulating genes involved in the metabolism and excretion of xenobiotics, drugs, and endogenous compounds. Activated by a broad range of endogenous steroids (e.g. pregnenolone, progesterone) and xenobiotics, including the antibiotic rifampicin and certain plant-derived metabolites. Upon ligand binding, translocates to the nucleus, forms a heterodimer with the retinoid X receptor/RXR, and binds to response elements in target promoters, leading to transcriptional activation. Target genes include cytochrome P450 enzymes such as CYP3A4 and ATP-binding cassette transporters including ABCB1/MDR1","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O75469/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NR1I2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NR1I2","total_profiled":1310},"omim":[{"mim_id":"607623","title":"NPC INTRACELLULAR CHOLESTEROL TRANSPORTER 1; NPC1","url":"https://www.omim.org/entry/607623"},{"mim_id":"604843","title":"SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B1; SLCO1B1","url":"https://www.omim.org/entry/604843"},{"mim_id":"603826","title":"NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 4; NR1H4","url":"https://www.omim.org/entry/603826"},{"mim_id":"603065","title":"NUCLEAR RECEPTOR SUBFAMILY 1, GROUP I, MEMBER 2; NR1I2","url":"https://www.omim.org/entry/603065"},{"mim_id":"600338","title":"ARYLACETAMIDE DEACETYLASE; AADAC","url":"https://www.omim.org/entry/600338"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":29.4},{"tissue":"liver","ntpm":44.3}],"url":"https://www.proteinatlas.org/search/NR1I2"},"hgnc":{"alias_symbol":["ONR1","PXR","BXR","SXR","PAR2"],"prev_symbol":[]},"alphafold":{"accession":"O75469","domains":[{"cath_id":"3.30.50.10","chopping":"51-125","consensus_level":"high","plddt":91.7448,"start":51,"end":125},{"cath_id":"1.10.565.10","chopping":"146-175_193-209_235-296_313-430","consensus_level":"high","plddt":95.3365,"start":146,"end":430}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75469","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75469-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75469-F1-predicted_aligned_error_v6.png","plddt_mean":85.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NR1I2","jax_strain_url":"https://www.jax.org/strain/search?query=NR1I2"},"sequence":{"accession":"O75469","fasta_url":"https://rest.uniprot.org/uniprotkb/O75469.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75469/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75469"}},"corpus_meta":[{"pmid":"9784494","id":"PMC_9784494","title":"SXR, a novel steroid and xenobiotic-sensing nuclear receptor.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9784494","citation_count":783,"is_preprint":false},{"pmid":"11329060","id":"PMC_11329060","title":"The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.","date":"2001","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11329060","citation_count":707,"is_preprint":false},{"pmid":"11248086","id":"PMC_11248086","title":"An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11248086","citation_count":616,"is_preprint":false},{"pmid":"10462436","id":"PMC_10462436","title":"P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR.","date":"1999","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/10462436","citation_count":590,"is_preprint":false},{"pmid":"10935643","id":"PMC_10935643","title":"Humanized xenobiotic response in mice expressing nuclear receptor SXR.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10935643","citation_count":542,"is_preprint":false},{"pmid":"25920087","id":"PMC_25920087","title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.","date":"2015","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25920087","citation_count":410,"is_preprint":false},{"pmid":"12120277","id":"PMC_12120277","title":"PXR, CAR and drug metabolism.","date":"2002","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/12120277","citation_count":406,"is_preprint":false},{"pmid":"11114890","id":"PMC_11114890","title":"Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11114890","citation_count":391,"is_preprint":false},{"pmid":"17284330","id":"PMC_17284330","title":"CAR and PXR: the xenobiotic-sensing receptors.","date":"2006","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/17284330","citation_count":329,"is_preprint":false},{"pmid":"20727377","id":"PMC_20727377","title":"Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.","date":"2010","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20727377","citation_count":315,"is_preprint":false},{"pmid":"11981033","id":"PMC_11981033","title":"Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11981033","citation_count":302,"is_preprint":false},{"pmid":"12920130","id":"PMC_12920130","title":"Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12920130","citation_count":298,"is_preprint":false},{"pmid":"19427329","id":"PMC_19427329","title":"Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects.","date":"2009","source":"Molecular aspects of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19427329","citation_count":242,"is_preprint":false},{"pmid":"16054614","id":"PMC_16054614","title":"CAR and PXR: xenosensors of endocrine disrupters?","date":"2005","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/16054614","citation_count":214,"is_preprint":false},{"pmid":"19595610","id":"PMC_19595610","title":"PXR and CAR in energy metabolism.","date":"2009","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/19595610","citation_count":202,"is_preprint":false},{"pmid":"22554043","id":"PMC_22554043","title":"Role of CAR and PXR in xenobiotic sensing and metabolism.","date":"2012","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22554043","citation_count":191,"is_preprint":false},{"pmid":"18159929","id":"PMC_18159929","title":"Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response.","date":"2007","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/18159929","citation_count":187,"is_preprint":false},{"pmid":"21295138","id":"PMC_21295138","title":"Nuclear receptor PXR, transcriptional circuits and metabolic relevance.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21295138","citation_count":185,"is_preprint":false},{"pmid":"15364541","id":"PMC_15364541","title":"PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators.","date":"2004","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15364541","citation_count":174,"is_preprint":false},{"pmid":"29113993","id":"PMC_29113993","title":"PXR: More Than Just a Master Xenobiotic Receptor.","date":"2017","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29113993","citation_count":139,"is_preprint":false},{"pmid":"12822739","id":"PMC_12822739","title":"Drug-activated nuclear receptors CAR and PXR.","date":"2003","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12822739","citation_count":138,"is_preprint":false},{"pmid":"19240808","id":"PMC_19240808","title":"The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism.","date":"2009","source":"Nuclear receptor signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19240808","citation_count":136,"is_preprint":false},{"pmid":"27932985","id":"PMC_27932985","title":"Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-Talk of PXR with Other Nuclear Receptors via Coactivator Interactions.","date":"2016","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27932985","citation_count":134,"is_preprint":false},{"pmid":"19018724","id":"PMC_19018724","title":"PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics.","date":"2008","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19018724","citation_count":132,"is_preprint":false},{"pmid":"21801835","id":"PMC_21801835","title":"FXR and PXR: potential therapeutic targets in cholestasis.","date":"2011","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21801835","citation_count":131,"is_preprint":false},{"pmid":"23349477","id":"PMC_23349477","title":"PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23349477","citation_count":131,"is_preprint":false},{"pmid":"15581595","id":"PMC_15581595","title":"Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR.","date":"2005","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/15581595","citation_count":127,"is_preprint":false},{"pmid":"23327618","id":"PMC_23327618","title":"Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond.","date":"2013","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23327618","citation_count":126,"is_preprint":false},{"pmid":"11090943","id":"PMC_11090943","title":"Use of the nuclear receptor PXR to predict drug interactions.","date":"2000","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/11090943","citation_count":125,"is_preprint":false},{"pmid":"22889594","id":"PMC_22889594","title":"Targeting xenobiotic receptors PXR and CAR for metabolic diseases.","date":"2012","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22889594","citation_count":124,"is_preprint":false},{"pmid":"18305370","id":"PMC_18305370","title":"The roles of nuclear receptors CAR and PXR in hepatic energy metabolism.","date":"2008","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/18305370","citation_count":116,"is_preprint":false},{"pmid":"16684648","id":"PMC_16684648","title":"Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR).","date":"2006","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16684648","citation_count":115,"is_preprint":false},{"pmid":"16877263","id":"PMC_16877263","title":"PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity.","date":"2006","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16877263","citation_count":107,"is_preprint":false},{"pmid":"12573482","id":"PMC_12573482","title":"Functional and structural comparison of PXR and CAR.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12573482","citation_count":101,"is_preprint":false},{"pmid":"16101575","id":"PMC_16101575","title":"Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics.","date":"2005","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16101575","citation_count":98,"is_preprint":false},{"pmid":"25463033","id":"PMC_25463033","title":"Targeting xenobiotic receptors PXR and CAR in human diseases.","date":"2014","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/25463033","citation_count":94,"is_preprint":false},{"pmid":"32082968","id":"PMC_32082968","title":"PXR: a center of transcriptional regulation in cancer.","date":"2019","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/32082968","citation_count":91,"is_preprint":false},{"pmid":"24329114","id":"PMC_24329114","title":"Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.","date":"2013","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24329114","citation_count":89,"is_preprint":false},{"pmid":"15269186","id":"PMC_15269186","title":"Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes.","date":"2004","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15269186","citation_count":89,"is_preprint":false},{"pmid":"23330542","id":"PMC_23330542","title":"PXR antagonists and implication in drug metabolism.","date":"2013","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23330542","citation_count":85,"is_preprint":false},{"pmid":"19688601","id":"PMC_19688601","title":"Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines.","date":"2009","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19688601","citation_count":83,"is_preprint":false},{"pmid":"16101574","id":"PMC_16101574","title":"Structure and function of the human nuclear xenobiotic receptor PXR.","date":"2005","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16101574","citation_count":80,"is_preprint":false},{"pmid":"24315978","id":"PMC_24315978","title":"Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24315978","citation_count":79,"is_preprint":false},{"pmid":"27041449","id":"PMC_27041449","title":"Regulation of hepatic energy metabolism by the nuclear receptor PXR.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/27041449","citation_count":79,"is_preprint":false},{"pmid":"21920351","id":"PMC_21920351","title":"Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21920351","citation_count":79,"is_preprint":false},{"pmid":"18479261","id":"PMC_18479261","title":"A gut feeling of the PXR, PPAR and NF-kappaB connection.","date":"2008","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18479261","citation_count":74,"is_preprint":false},{"pmid":"27113289","id":"PMC_27113289","title":"RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/27113289","citation_count":70,"is_preprint":false},{"pmid":"33600998","id":"PMC_33600998","title":"The xenobiotic receptors PXR and CAR in liver physiology, an update.","date":"2021","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33600998","citation_count":68,"is_preprint":false},{"pmid":"12433065","id":"PMC_12433065","title":"The nuclear receptor PXR: a master regulator of \"homeland\" defense.","date":"2002","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/12433065","citation_count":67,"is_preprint":false},{"pmid":"20861742","id":"PMC_20861742","title":"Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.","date":"2010","source":"Journal of acquired immune deficiency syndromes (1999)","url":"https://pubmed.ncbi.nlm.nih.gov/20861742","citation_count":65,"is_preprint":false},{"pmid":"33142929","id":"PMC_33142929","title":"Regulation of CAR and PXR Expression in Health and Disease.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33142929","citation_count":64,"is_preprint":false},{"pmid":"26921498","id":"PMC_26921498","title":"Small-molecule modulators of PXR and CAR.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26921498","citation_count":60,"is_preprint":false},{"pmid":"36111293","id":"PMC_36111293","title":"The role of pregnane X receptor (PXR) in substance metabolism.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36111293","citation_count":60,"is_preprint":false},{"pmid":"19505191","id":"PMC_19505191","title":"Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.","date":"2009","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/19505191","citation_count":59,"is_preprint":false},{"pmid":"9573044","id":"PMC_9573044","title":"BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9573044","citation_count":59,"is_preprint":false},{"pmid":"32404507","id":"PMC_32404507","title":"Nuclear receptor PXR targets AKR1B7 to protect mitochondrial metabolism and renal function in AKI.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32404507","citation_count":58,"is_preprint":false},{"pmid":"23599746","id":"PMC_23599746","title":"Expression of the PXR gene in various types of cancer and drug resistance.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23599746","citation_count":58,"is_preprint":false},{"pmid":"29709908","id":"PMC_29709908","title":"Effects of Oridonin on Hepatic Cytochrome P450 Expression and Activities in PXR-Humanized Mice.","date":"2018","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/29709908","citation_count":55,"is_preprint":false},{"pmid":"18072748","id":"PMC_18072748","title":"PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks.","date":"2007","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/18072748","citation_count":54,"is_preprint":false},{"pmid":"27709012","id":"PMC_27709012","title":"PXR variants: the impact on drug metabolism and therapeutic responses.","date":"2016","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/27709012","citation_count":53,"is_preprint":false},{"pmid":"19415465","id":"PMC_19415465","title":"Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.","date":"2009","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/19415465","citation_count":53,"is_preprint":false},{"pmid":"7479793","id":"PMC_7479793","title":"Y chromosome short arm-Sxr recombination in XSxr/Y males causes deletion of Rbm and XY female sex reversal.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7479793","citation_count":52,"is_preprint":false},{"pmid":"29757018","id":"PMC_29757018","title":"A current structural perspective on PXR and CAR in drug metabolism.","date":"2018","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29757018","citation_count":51,"is_preprint":false},{"pmid":"33097284","id":"PMC_33097284","title":"Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine.","date":"2020","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33097284","citation_count":50,"is_preprint":false},{"pmid":"19123943","id":"PMC_19123943","title":"Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19123943","citation_count":50,"is_preprint":false},{"pmid":"27709013","id":"PMC_27709013","title":"A brief history of the discovery of PXR and CAR as xenobiotic receptors.","date":"2016","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/27709013","citation_count":49,"is_preprint":false},{"pmid":"17507630","id":"PMC_17507630","title":"Phytoestrogen exposure is associated with circulating sex hormone levels in postmenopausal women and interact with ESR1 and NR1I2 gene variants.","date":"2007","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17507630","citation_count":49,"is_preprint":false},{"pmid":"33076328","id":"PMC_33076328","title":"PXR Functionally Interacts with NF-κB and AP-1 to Downregulate the Inflammation-Induced Expression of Chemokine CXCL2 in Mice.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33076328","citation_count":47,"is_preprint":false},{"pmid":"38067179","id":"PMC_38067179","title":"AhR, PXR and CAR: From Xenobiotic Receptors to Metabolic Sensors.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38067179","citation_count":45,"is_preprint":false},{"pmid":"21733184","id":"PMC_21733184","title":"Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21733184","citation_count":44,"is_preprint":false},{"pmid":"18629309","id":"PMC_18629309","title":"Activation of steroid and xenobiotic receptor (SXR, NR1I2) and its orthologs in laboratory, toxicologic, and genome model species.","date":"2008","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/18629309","citation_count":44,"is_preprint":false},{"pmid":"35011625","id":"PMC_35011625","title":"The Nuclear Receptor PXR in Chronic Liver Disease.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35011625","citation_count":43,"is_preprint":false},{"pmid":"23237007","id":"PMC_23237007","title":"Pregnane X receptor (PXR) at the crossroads of human metabolism and disease.","date":"2013","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23237007","citation_count":40,"is_preprint":false},{"pmid":"21933665","id":"PMC_21933665","title":"Energy sensing factors PGC-1α and SIRT1 modulate PXR expression and function.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21933665","citation_count":40,"is_preprint":false},{"pmid":"26643981","id":"PMC_26643981","title":"RXRα, PXR and CAR xenobiotic receptors mediate the apoptotic and neurotoxic actions of nonylphenol in mouse hippocampal cells.","date":"2015","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26643981","citation_count":40,"is_preprint":false},{"pmid":"22242859","id":"PMC_22242859","title":"Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders.","date":"2012","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22242859","citation_count":38,"is_preprint":false},{"pmid":"21622216","id":"PMC_21622216","title":"Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21622216","citation_count":37,"is_preprint":false},{"pmid":"35159123","id":"PMC_35159123","title":"Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35159123","citation_count":36,"is_preprint":false},{"pmid":"29703383","id":"PMC_29703383","title":"PXR as a mediator of herb-drug interaction.","date":"2017","source":"Journal of food and drug analysis","url":"https://pubmed.ncbi.nlm.nih.gov/29703383","citation_count":36,"is_preprint":false},{"pmid":"35646519","id":"PMC_35646519","title":"PXR activation impairs hepatic glucose metabolism partly via inhibiting the HNF4α-GLUT2 pathway.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35646519","citation_count":36,"is_preprint":false},{"pmid":"21830270","id":"PMC_21830270","title":"Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease.","date":"2010","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21830270","citation_count":34,"is_preprint":false},{"pmid":"27295009","id":"PMC_27295009","title":"Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk.","date":"2016","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27295009","citation_count":33,"is_preprint":false},{"pmid":"24166671","id":"PMC_24166671","title":"Pregnane X receptor (PXR)--a contributor to the diabetes epidemic?","date":"2014","source":"Drug metabolism and drug interactions","url":"https://pubmed.ncbi.nlm.nih.gov/24166671","citation_count":33,"is_preprint":false},{"pmid":"31614203","id":"PMC_31614203","title":"Patchouli alcohol activates PXR and suppresses the NF-κB-mediated intestinal inflammatory.","date":"2019","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31614203","citation_count":33,"is_preprint":false},{"pmid":"36119030","id":"PMC_36119030","title":"Role of nuclear receptor PXR in immune cells and inflammatory diseases.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36119030","citation_count":30,"is_preprint":false},{"pmid":"26924429","id":"PMC_26924429","title":"Novel functions of PXR in cardiometabolic disease.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26924429","citation_count":29,"is_preprint":false},{"pmid":"23299080","id":"PMC_23299080","title":"3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR.","date":"2013","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/23299080","citation_count":27,"is_preprint":false},{"pmid":"35002522","id":"PMC_35002522","title":"Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35002522","citation_count":27,"is_preprint":false},{"pmid":"25680588","id":"PMC_25680588","title":"Environmental contaminants activate human and polar bear (Ursus maritimus) pregnane X receptors (PXR, NR1I2) differently.","date":"2015","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25680588","citation_count":27,"is_preprint":false},{"pmid":"21977915","id":"PMC_21977915","title":"Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma.","date":"2011","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21977915","citation_count":27,"is_preprint":false},{"pmid":"34439808","id":"PMC_34439808","title":"Pregnane X Receptor (PXR) Polymorphisms and Cancer Treatment.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34439808","citation_count":26,"is_preprint":false},{"pmid":"26883953","id":"PMC_26883953","title":"A SUMO-acetyl switch in PXR biology.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26883953","citation_count":26,"is_preprint":false},{"pmid":"33127475","id":"PMC_33127475","title":"Pregnane X receptor (PXR) protects against cisplatin-induced acute kidney injury in mice.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33127475","citation_count":26,"is_preprint":false},{"pmid":"30778091","id":"PMC_30778091","title":"Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30778091","citation_count":24,"is_preprint":false},{"pmid":"23701014","id":"PMC_23701014","title":"PXR cross-talks with internal and external signals in physiological and pathophysiological responses.","date":"2013","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23701014","citation_count":24,"is_preprint":false},{"pmid":"35184041","id":"PMC_35184041","title":"Distinct Roles of the Sister Nuclear Receptors PXR and CAR in Liver Cancer Development.","date":"2022","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/35184041","citation_count":24,"is_preprint":false},{"pmid":"18583127","id":"PMC_18583127","title":"Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).","date":"2008","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/18583127","citation_count":24,"is_preprint":false},{"pmid":"31226734","id":"PMC_31226734","title":"New Aspects of Vitamin K Research with Synthetic Ligands: Transcriptional Activity via SXR and Neural Differentiation Activity.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31226734","citation_count":24,"is_preprint":false},{"pmid":"27233963","id":"PMC_27233963","title":"Human Xenobiotic Nuclear Receptor PXR Augments Mycobacterium tuberculosis Survival.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27233963","citation_count":24,"is_preprint":false},{"pmid":"16101576","id":"PMC_16101576","title":"Beyond CAR and PXR.","date":"2005","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16101576","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41881,"output_tokens":7292,"usd":0.117512,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16557,"output_tokens":5263,"usd":0.10718,"stage2_stop_reason":"end_turn"},"total_usd":0.224692,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"SXR (NR1I2) was identified as a novel nuclear receptor that activates transcription in response to a diversity of natural and synthetic steroid and xenobiotic compounds. It forms a heterodimer with RXR that binds to and induces transcription from response elements present in steroid-inducible cytochrome P-450 genes (CYP3A). SXR is expressed in liver and intestine, the same tissues where these catabolic enzymes are expressed.\",\n      \"method\": \"Receptor cloning, transactivation assays, heterodimer binding/RXR co-transfection, tissue expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — original cloning paper with in vitro transactivation, heterodimer reconstitution, and DNA binding; foundational work replicated extensively\",\n      \"pmids\": [\"9784494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BXR (an NR1I2 ortholog/related receptor) heterodimerizes with RXR and binds high-affinity DNA sites composed of a variant thyroid hormone response element. Alkyl esters of amino and hydroxy benzoic acids (benzoates) were identified as bona fide BXR ligands by in vitro cofactor association studies and competitive radiolabeled compound binding, establishing benzoates as a new molecular class of nuclear receptor ligand.\",\n      \"method\": \"Receptor cloning, in vitro ligand binding (radiolabeled compound displacement), cofactor association studies, mass spectrometry, 1H NMR, transactivation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods including radiolabeled binding, NMR, MS, and functional transactivation in single study\",\n      \"pmids\": [\"9573044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Targeted disruption of mouse PXR (NR1I2) abolishes induction of CYP3A by prototypic inducers dexamethasone and pregnenolone-16α-carbonitrile (PCN), establishing PXR as the necessary mediator of CYP3A induction. Transgenic mice expressing an activated form of human SXR showed constitutive upregulation of CYP3A gene expression and enhanced protection against toxic xenobiotic compounds. The species origin of the receptor (not promoter structure) dictates species-specific CYP3A inducibility.\",\n      \"method\": \"PXR knockout mice, transgenic mice expressing activated SXR, CYP3A gene expression analysis, xenobiotic toxicity assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and transgenic gain-of-function in vivo, replicated across labs\",\n      \"pmids\": [\"10935643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SXR/PXR can regulate CYP2B genes (not only CYP3A) via adaptive recognition of the phenobarbital response element (PBRE) in cultured cells and transgenic mice, revealing cross-regulation of CYP gene families. Reciprocally, orphan receptor CAR activates CYP3A through SXR/PXR response elements, establishing a metabolic safety net of overlapping xenobiotic receptor function.\",\n      \"method\": \"Transactivation assays in cultured cells, transgenic mouse studies, reporter gene assays with CYP2B PBRE and CYP3A XREM\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-based and in vivo transgenic experiments confirming cross-regulation; replicated concept\",\n      \"pmids\": [\"11114890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SXR/PXR directly regulates MDR1 gene expression (encoding P-glycoprotein/ABCB1), coordinating both drug catabolism (CYP3A4) and drug efflux. Paclitaxel activated SXR and enhanced P-glycoprotein-mediated drug clearance, while docetaxel did not activate SXR. Docetaxel's inactivity was linked to its inability to displace transcriptional corepressors from SXR. ET-743 suppressed MDR1 transcription by acting as an SXR inhibitor.\",\n      \"method\": \"Reporter gene assays, RT-PCR for MDR1/CYP3A4 expression, corepressor displacement assays, pharmacokinetic studies\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic demonstration of MDR1 as SXR target with corepressor displacement mechanism; multiple orthogonal methods\",\n      \"pmids\": [\"11329060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human SXR and rodent PXR function as bile acid receptors; the secondary bile acid lithocholic acid (LCA) is a metabolic substrate for CYP3A hydroxylation and activates SXR/PXR. Using PXR knockout and SXR transgenic animals, SXR/PXR activation was shown to be necessary and sufficient to induce CYP3A enzymes and confer resistance to LCA hepatotoxicity, as well as to other xenotoxicants.\",\n      \"method\": \"PXR knockout mice, transgenic mice, LCA toxicity assays, CYP3A induction assays, cell-based transactivation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with both KO and transgenic overexpression; multiple ligands and phenotypic readouts\",\n      \"pmids\": [\"11248086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Comparative pharmacological profiling of NR1I subfamily members identified three distinct receptor classes: PXRs (activated by broad range of xenobiotics and steroids), CARs (high basal activity, generally repressed), and BXRs (selectively activated by benzoate analogs). PXRs possess a unique H1-3 insert (stretch of amino acids between helices 1 and 3 absent in CARs and BXRs) that modeling suggests expands the ligand binding pocket by facilitating unwinding of helices 6 and 7, explaining PXR promiscuity.\",\n      \"method\": \"Ligand activation assays of LBD fusion proteins across species, structural modeling, sequence analysis\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — systematic pharmacological profiling with structural modeling; modeling is computational but supported by functional ligand data\",\n      \"pmids\": [\"11981033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Vitamin K2 (menaquinone) binds to and activates the orphan nuclear receptor SXR/PXR and induces expression of the SXR target gene CYP3A4, identifying it as a bona fide SXR ligand. Vitamin K2 treatment increased mRNA levels for osteoblast markers (bone alkaline phosphatase, osteoprotegerin, osteopontin, matrix Gla protein) in osteosarcoma cells. Vitamin K2 could induce bone markers in primary osteocytes from wild-type but not PXR-deficient mice, establishing SXR as a mediator of bone homeostasis.\",\n      \"method\": \"Ligand binding assays, CYP3A4 reporter assays, RT-PCR, primary osteocyte cultures from PXR knockout mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ligand binding, reporter assay, and PXR-KO genetic validation in primary cells; multiple orthogonal methods\",\n      \"pmids\": [\"12920130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PXR (NR1I2) is expressed in many tissues beyond liver and intestine, including human bone marrow and select regions of human brain. Multiple alternatively spliced PXR isoforms (PXR.2 lacking 37 aa from LBD, PXR.3 lacking 41 aa from LBD) were identified. Neurosteroids allopregnanolone and pregnanolone activated PXR and induced CYP3A4-luciferase reporter transcription. Nicotine was identified as an efficacious PXR activator inducing CYP3A4 transcription.\",\n      \"method\": \"RT-PCR across 36 human tissues, CYP3A4-luciferase reporter assays, quantitative mRNA analysis in human liver\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — cell-based transactivation assays for novel ligands; tissue expression by RT-PCR; single lab, multiple methods\",\n      \"pmids\": [\"15364541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"All four tocotrienols (but not tocopherols) specifically bind to and activate SXR/PXR. Tocotrienols show tissue-specific induction of SXR target genes: they upregulate CYP3A4 but not UGT1A1 or MDR1 in primary hepatocytes, whereas in intestinal LS180 cells they induce MDR1 and UGT1A1 but not CYP3A4. Unliganded SXR interacts with NCoR (nuclear receptor corepressor), and this interaction is only partially disrupted by tocotrienols; NCoR is expressed at higher levels in LS180 cells, contributing to tissue-specific gene regulation.\",\n      \"method\": \"Ligand binding assays, reporter gene assays, RT-PCR in primary hepatocytes and LS180 cells, co-immunoprecipitation of SXR-NCoR, dominant-negative NCoR overexpression\",\n      \"journal\": \"Drug metabolism and disposition: the biological fate of chemicals\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ligand binding, protein-protein interaction (co-IP), functional reporter assays with dominant-negative rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15269186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Activation of SXR/PXR in p53 wild-type breast cancer cells (MCF-7, ZR-75-1) inhibited proliferation by inducing G1/S cell cycle arrest and apoptosis. This was mechanistically dependent on SXR-induced upregulation of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production, leading to p53 stabilization and upregulation of p21, PUMA, and BAX. siRNA knockdown of SXR blocked iNOS induction; p53 knockdown blocked p21 and BAX upregulation.\",\n      \"method\": \"Cell proliferation assays, FACS cell cycle analysis, RT-PCR, western blotting, siRNA knockdown of SXR and p53, iNOS inhibition\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with specific mechanistic phenotype; multiple pathway components validated; single lab\",\n      \"pmids\": [\"19123943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PGC-1α overexpression upregulates PXR expression in mouse primary hepatocytes, and siRNA knockdown of PPARα attenuates PGC-1α-mediated induction of PXR mRNA, indicating PPARα mediates PGC-1α's effect on PXR transcription. SIRT1 interacts with PXR (by co-immunoprecipitation) and pyruvate/SIRT1 activation interferes with PXR-PGC-1α interaction in mammalian two-hybrid assays, inhibiting synergistic CYP3A11 induction.\",\n      \"method\": \"PGC-1α overexpression and siRNA knockdown in primary hepatocytes, mammalian two-hybrid assay, co-immunoprecipitation, RT-PCR\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and two-hybrid for protein-protein interaction, siRNA knockdown, functional gene expression; single lab, multiple methods\",\n      \"pmids\": [\"21933665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Metformin suppresses PXR-mediated CYP3A4 expression in human hepatocytes. Mechanistically, metformin disrupts PXR's interaction with steroid receptor coactivator-1 (SRC1) in a two-hybrid assay independently of the PXR ligand binding pocket. Metformin suppressed Cyp3a11 mRNA in wild-type but not Pxr−/− mice. AMPK activation and SHP upregulation were not required for this effect.\",\n      \"method\": \"Reporter gene assays, qRT-PCR in human hepatocytes and Pxr−/− mice, mammalian two-hybrid assay for PXR-SRC1 interaction, AMPK inhibition studies\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (Pxr-KO mice) and biochemical (two-hybrid) validation across multiple systems; mechanism of coactivator disruption established\",\n      \"pmids\": [\"21920351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In colon cancer cells, SN-38 (active metabolite of irinotecan) activates endogenous SXR/PXR, causing its translocation into the nucleus where it associates with RXR. ChIP demonstrated that endogenous SXR binds to the native CYP3A4 gene promoter upon activation. siRNA confirmed SXR involvement in CYP3A4 overexpression and identified CYP3A5 and MRP2 transporter as SXR target genes. SXR overexpression reduced cellular sensitivity to irinotecan.\",\n      \"method\": \"Immunofluorescence (nuclear translocation), ChIP, siRNA knockdown, RT-PCR, drug sensitivity assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP on native promoter, nuclear translocation imaging, siRNA knockdown; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"21733184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PXR ablation in mice inhibited high-fat diet-induced obesity, hepatic steatosis, and insulin resistance through increased oxygen consumption, increased mitochondrial β-oxidation, inhibition of hepatic lipogenesis and inflammation, and sensitization of insulin signaling. Mechanistically, PXR ablation was associated with inhibition of c-Jun N-terminal kinase (JNK) activation and downregulation of lipin-1, identified as a novel PXR target gene. PXR ablation in ob/ob mice also improved metabolic phenotype.\",\n      \"method\": \"PXR knockout mice on HFD and ob/ob background, oxygen consumption measurements, euglycemic clamp, RT-PCR, lipin-1 promoter/target gene analysis\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic mouse models with defined mechanistic pathway (JNK, lipin-1 as target); multiple metabolic phenotypic readouts\",\n      \"pmids\": [\"23349477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PXR is modified by acetylation on lysine residues. Increased acetylation of PXR stimulates its increased SUMOylation to support active transcriptional suppression (a 'SUMO-acetyl switch'). Pharmacologic inhibition of lysine deacetylation with trichostatin A (TSA) alters PXR subcellular localization in cultured hepatocytes and profoundly impacts PXR transactivation capacity. PXR associates with the lysine deacetylating enzyme HDAC3 in a complex with SMRT corepressor.\",\n      \"method\": \"Mass spectrometry identification of acetylation sites, cell-based transactivation assays with TSA, immunofluorescence for subcellular localization, co-immunoprecipitation of PXR-HDAC3-SMRT complex, SUMOylation assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification of PTM, co-IP for protein complex, functional localization and transactivation data; single lab, multiple methods\",\n      \"pmids\": [\"26883953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PXR was robustly downregulated in kidneys with acute kidney injury (AKI). PXR targeted Aldo-keto reductase family 1 member B7 (AKR1B7) to improve mitochondrial function, determined by luciferase reporter assays and genomic manipulation. Silencing PXR in rats enhanced cisplatin-induced AKI with severe mitochondrial abnormalities; activating PXR protected against AKI. The PXR/AKR1B7/mitochondrial metabolism axis was validated in ischemia/reperfusion AKI model.\",\n      \"method\": \"Luciferase reporter assays, genomic manipulation (PXR silencing and activation), proteomics, cisplatin and ischemia/reperfusion AKI models in rats, renal function assays\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vivo genetic models, reporter assays, proteomics; AKR1B7 identified as direct target by genomic and pharmacological approaches\",\n      \"pmids\": [\"32404507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PXR functionally interacts with both NF-κB and AP-1 transcription factors to downregulate inflammation-induced expression of chemokine CXCL2 in mouse liver. Reporter assays with mutated Cxcl2 promoter showed that mutation of both NF-κB and AP-1 binding sites abolished PXR-dependent suppression; mutation of either alone only partially reduced it. PXR activation (PCN) suppressed neutrophil infiltration and plasma transaminase activity in CCl4-injured mice.\",\n      \"method\": \"In vivo mouse liver injury model, qRT-PCR, reporter assays with wild-type and NF-κB/AP-1 mutated Cxcl2 promoters, plasma transaminase assays, histology\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed promoter mutagenesis reporter assays and in vivo validation; single lab\",\n      \"pmids\": [\"33076328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PXR activation impaired hepatic glucose metabolism by inhibiting the HNF4α–GLUT2 pathway. PXR agonists downregulated HNF4α and GLUT2 expression; PXR overexpression decreased and PXR silencing increased HNF4α/GLUT2. HNF4α recruits to the Slc2a2 (GLUT2) promoter, and PCN suppressed this recruitment. Liver-specific Hnf4α deletion and PCN treatment impaired glucose tolerance and hepatic glucose uptake in mice.\",\n      \"method\": \"HepG2 cells and mouse/human primary hepatocytes with PXR overexpression/silencing, ChIP for HNF4α at Slc2a2 promoter, luciferase reporter assays, liver-specific Hnf4α knockout mice, glucose tolerance tests\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, promoter reporter assays, multiple genetic models (KO mice, siRNA) across human and mouse systems; mechanistic pathway established\",\n      \"pmids\": [\"35646519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Human PXR (hPXR) interacts with mycobacterial cell wall lipids (particularly mycolic acids) via its promiscuous ligand binding domain, as shown in macrophage infection studies. hPXR augments M. tuberculosis survival inside host macrophages by promoting foamy macrophage formation and abrogating phagolysosomal fusion, inflammation, and apoptosis. Expression of hPXR in humanized transgenic mice promoted M. tuberculosis survival in vivo.\",\n      \"method\": \"Human monocyte-derived macrophages, hPXR-transgenic mice, phagolysosomal fusion assays, lipid ligand binding studies, infection survival assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ligand-binding domain interaction with mycolic acids, in vitro macrophage studies, and hPXR transgenic mouse in vivo validation; single lab\",\n      \"pmids\": [\"27233963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Upon stimulation with lithocholic acid, PXR translocates from cytoplasm to the nucleus of OE19 adenocarcinoma cells, as demonstrated by immunofluorescence in cell line experiments.\",\n      \"method\": \"Immunohistochemistry and immunofluorescence in esophageal cell lines and tissue, PXR stimulation with lithocholic acid\",\n      \"journal\": \"BMC gastroenterology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single localization observation in cell line without functional consequence measured; single lab, single method\",\n      \"pmids\": [\"21977915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In mouse hippocampal neurons, nonylphenol induced translocation of PXR immunofluorescence from cytoplasm to the nucleus. siRNA knockdown of Pxr reduced nonylphenol-induced caspase-3 activation and LDH release, demonstrating that PXR signaling contributes to nonylphenol-induced apoptosis and neurotoxicity.\",\n      \"method\": \"Primary mouse hippocampal cell cultures, immunofluorescence for nuclear translocation, siRNA knockdown, caspase-3 activity assay, LDH release assay\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA genetic knockdown with specific phenotypic readouts and localization imaging; single lab, multiple methods\",\n      \"pmids\": [\"26643981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PXR transcript variant 1 (PXR1) interacts with p53, whereas PXR transcript variant 3 (PXR3) does not, establishing a differential protein-protein interaction profile of PXR isoforms. Variants PXR3 and PXR4 do not induce target gene expression upon agonist treatment, whereas PXR1 and PXR2 do. PXR1 and PXR4 mRNA are downregulated by methylation in cancerous tissue.\",\n      \"method\": \"Protein-protein interaction assays (PXR1 vs PXR3 with p53), reporter gene assays for target gene transactivation, methylation analysis\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single-method protein interaction data for isoforms; functional differences established but limited mechanistic depth reported in abstract\",\n      \"pmids\": [\"27709012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PXR activates a SREBP-independent lipogenic pathway by inducing expression of the free fatty acid uptake transporter CD36, PPARγ, and accessory lipogenic enzymes stearoyl-CoA desaturase-1 (SCD-1) and long-chain free fatty acid elongase (FAE) in a liver-specific manner. Promoter analysis established CD36 as a transcriptional target of PXR. PPARγ is also a direct transcriptional target of PXR.\",\n      \"method\": \"Promoter analysis/reporter assays, RT-PCR for target gene expression, liver-specific expression analysis\",\n      \"journal\": \"Molecular pharmaceutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — promoter analysis and gene expression data establishing CD36 and PPARγ as direct PXR targets; single lab\",\n      \"pmids\": [\"18072748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Patchouli alcohol (PA) activates PXR (identified as a PXR agonist by hPXR transactivation assays and CYP3A4 expression/activity induction). PA-mediated PXR activation attenuated NF-κB activity and nuclear translocation. PXR knockdown abolished the anti-inflammatory effect of PA on NF-κB, demonstrating that the anti-inflammatory effect is PXR-dependent. In vivo, PA prevented DSS-induced colitis by regulating PXR/NF-κB signaling.\",\n      \"method\": \"hPXR transactivation assays, NF-κB luciferase assays, NF-κB nuclear translocation imaging, PXR knockdown, DSS colitis mouse model, pharmacological PXR inhibition\",\n      \"journal\": \"Journal of ethnopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown and pharmacological inhibition validate PXR-NF-κB mechanistic link; in vitro and in vivo; single lab\",\n      \"pmids\": [\"31614203\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NR1I2/PXR/SXR is a ligand-activated nuclear receptor that heterodimerizes with RXRα, binds xenobiotic response elements in gene promoters, and functions as a broad-specificity sensor of steroids, bile acids, and xenobiotics to transcriptionally induce phase I (CYP3A4, CYP2B) and phase II drug-metabolizing enzymes and transporters (MDR1/P-gp, MRP2); it also regulates energy metabolism (lipogenesis via CD36/PPARγ, gluconeogenesis via HNF4α–GLUT2 pathway), bile acid detoxification (CYP3A-mediated LCA hydroxylation), bone homeostasis (via vitamin K2 signaling), and inflammation (by suppressing NF-κB and AP-1), with its transcriptional activity modulated by post-translational modifications including phosphorylation, acetylation (by HDAC3/SMRT complex), and SUMOylation, as well as coactivator (SRC1, PGC-1α) and corepressor (NCoR, SMRT) interactions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NR1I2 (SXR/PXR) is a ligand-activated nuclear receptor that functions as a broad-specificity sensor of steroids, bile acids, and xenobiotics, heterodimerizing with RXR and binding response elements in target gene promoters to induce drug-metabolizing enzymes and transporters in liver and intestine [#0, #13]. Its defining role is xenobiotic detoxification: it is the necessary and sufficient mediator of CYP3A induction by prototypic inducers, conferring protection against toxic compounds in vivo [#2], and it coordinately controls cross-regulated CYP families through the phenobarbital response element [#3] as well as drug efflux via MDR1/P-glycoprotein and MRP2 to integrate catabolism with clearance [#4, #13]. PXR is endogenously activated by the secondary bile acid lithocholic acid, driving CYP3A-mediated hydroxylation that detoxifies bile acids [#5], and its unusually large, flexible ligand-binding pocket—conferred by a unique H1-3 insert—accommodates an exceptionally diverse ligand set including vitamin K2, tocotrienols, neurosteroids, nicotine, and bacterial mycolic acids [#6, #7, #9, #8, #19]. Beyond detoxification, NR1I2 regulates energy metabolism, promoting a SREBP-independent lipogenic program via CD36 and PPARγ [#23], impairing hepatic glucose handling by suppressing the HNF4α–GLUT2 pathway [#18], and driving diet-induced obesity and insulin resistance through JNK activation and lipin-1 induction [#14]. It also suppresses inflammation by antagonizing NF-κB and AP-1 to downregulate chemokines such as CXCL2 [#17, #24], mediates vitamin K2-dependent bone homeostasis [#7], and exhibits tissue-protective metabolic functions, as in the PXR/AKR1B7/mitochondrial axis in acute kidney injury [#16]. Its transcriptional output is tuned by coactivators (SRC1, PGC-1α) and corepressors (NCoR, SMRT) and by post-translational modification, including an acetylation–SUMOylation switch executed in complex with HDAC3/SMRT [#9, #11, #12, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established the existence and basic mechanism of NR1I2 as a xenobiotic-responsive nuclear receptor, answering whether a single receptor could couple diverse chemical sensing to CYP3A induction.\",\n      \"evidence\": \"Receptor cloning, RXR heterodimer reconstitution, transactivation and DNA-binding assays, tissue expression analysis\",\n      \"pmids\": [\"9784494\", \"9573044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological ligands not yet defined\", \"In vivo requirement not established by genetics\", \"Structural basis of ligand promiscuity unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Genetic knockout and gain-of-function transgenics proved PXR is the necessary in vivo mediator of CYP3A induction and that receptor species origin dictates inducibility, moving the receptor from in vitro candidate to physiological detoxification sensor.\",\n      \"evidence\": \"Pxr knockout and activated-SXR transgenic mice, CYP3A expression and xenobiotic toxicity assays\",\n      \"pmids\": [\"10935643\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous activating ligands not yet identified\", \"Scope of target gene network beyond CYP3A unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed NR1I2 cross-regulates CYP2B via the PBRE and shares response elements reciprocally with CAR, establishing a redundant xenobiotic-response safety net rather than a single-gene regulator.\",\n      \"evidence\": \"Transactivation and reporter assays, transgenic mice with CYP2B PBRE and CYP3A XREM\",\n      \"pmids\": [\"11114890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each receptor in vivo not resolved\", \"Determinants of element selectivity unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified MDR1/P-glycoprotein as a direct PXR target and revealed corepressor displacement as the discriminator between activating and non-activating ligands, linking drug catabolism with efflux clearance.\",\n      \"evidence\": \"Reporter assays, RT-PCR, corepressor displacement assays, pharmacokinetics with paclitaxel/docetaxel/ET-743\",\n      \"pmids\": [\"11329060\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of displaced corepressors not fully mapped here\", \"Genome-wide transporter target set undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated NR1I2 is a bile acid receptor and that LCA is both a ligand and a CYP3A substrate, establishing a feed-forward detoxification loop necessary and sufficient for LCA resistance.\",\n      \"evidence\": \"Pxr knockout and transgenic mice, LCA toxicity and CYP3A induction assays, cell-based transactivation\",\n      \"pmids\": [\"11248086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other endogenous bile acid ligands not exhaustively profiled\", \"Quantitative flux of LCA clearance not measured\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Comparative profiling across NR1I subfamily attributed PXR promiscuity to a unique H1-3 insert that enlarges the ligand-binding pocket, providing a structural rationale for broad ligand sensing.\",\n      \"evidence\": \"LBD fusion-protein activation assays across species, structural modeling, sequence analysis\",\n      \"pmids\": [\"11981033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pocket-expansion model is computational, not crystallographic\", \"Helix unwinding mechanism not experimentally resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified vitamin K2 as a bona fide PXR ligand mediating osteoblast marker induction, extending NR1I2 function from detoxification into bone homeostasis.\",\n      \"evidence\": \"Ligand binding, CYP3A4 reporter assays, RT-PCR, primary osteocytes from Pxr-knockout mice\",\n      \"pmids\": [\"12920130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct bone marker genes as PXR targets not promoter-mapped\", \"In vivo skeletal phenotype of Pxr loss not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Expanded the ligand repertoire (neurosteroids, nicotine, tocotrienols) and tissue distribution, and showed NCoR corepressor levels drive tissue-specific target gene selection, explaining context-dependent PXR output.\",\n      \"evidence\": \"RT-PCR across 36 tissues, CYP3A4-luciferase reporters, ligand binding, SXR-NCoR co-IP, dominant-negative NCoR\",\n      \"pmids\": [\"15364541\", \"15269186\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional roles of alternatively spliced isoforms unclear\", \"Mechanism of differential NCoR release by ligand not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined a SREBP-independent lipogenic program controlled by PXR through direct induction of CD36 and PPARγ, establishing NR1I2 as a regulator of hepatic lipid metabolism.\",\n      \"evidence\": \"Promoter/reporter analysis, RT-PCR for CD36/PPARγ/SCD-1/FAE, liver-specific expression\",\n      \"pmids\": [\"18072748\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo metabolic consequence not tested in this study\", \"Promoter binding shown only for subset of targets\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected NR1I2 to coactivator/coregulator energy-sensing networks (PGC-1α, PPARα, SIRT1) and to a p53/iNOS tumor-suppressive program, broadening its regulatory inputs and outputs.\",\n      \"evidence\": \"PGC-1α overexpression/siRNA, mammalian two-hybrid, co-IP, siRNA of SXR/p53, iNOS inhibition in breast cancer cells\",\n      \"pmids\": [\"21933665\", \"19123943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect coregulator effects partly inferred\", \"Cancer-cell-type specificity of p53/iNOS axis unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that NR1I2 activity is modulated by ligand-independent coactivator disruption (metformin–SRC1) and confirmed activation-dependent nuclear translocation and native-promoter binding, refining the activation mechanism.\",\n      \"evidence\": \"Two-hybrid PXR-SRC1, reporter/qRT-PCR in human hepatocytes and Pxr-KO mice, ChIP on native CYP3A4 promoter, nuclear-translocation imaging, drug sensitivity assays\",\n      \"pmids\": [\"21920351\", \"21733184\", \"21977915\", \"27709012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of pocket-independent SRC1 disruption unknown\", \"Isoform-specific interaction differences (PXR1 vs PXR3) carry low-confidence support\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked NR1I2 to systemic metabolic disease, showing Pxr ablation protects against diet-induced obesity and insulin resistance via JNK and the novel target lipin-1.\",\n      \"evidence\": \"Pxr-KO mice on HFD and ob/ob backgrounds, oxygen consumption, euglycemic clamp, RT-PCR, lipin-1 analysis\",\n      \"pmids\": [\"23349477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contribution of PXR not dissected\", \"Relationship between lipogenic CD36/PPARγ program and lipin-1 axis unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established post-translational control of NR1I2 through an acetylation–SUMOylation switch executed in an HDAC3/SMRT complex, and a host-pathogen role via mycolic acid binding, deepening regulatory and immunological mechanism.\",\n      \"evidence\": \"Mass spectrometry of acetylation sites, TSA transactivation assays, localization imaging, PXR-HDAC3-SMRT co-IP, SUMOylation assays; macrophage infection and hPXR-transgenic mice\",\n      \"pmids\": [\"26883953\", \"27233963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymes writing/erasing the SUMO-acetyl switch only partly defined\", \"Physiological triggers of the modification switch unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified tissue-protective and anti-inflammatory mechanisms, defining the PXR/AKR1B7/mitochondrial axis in kidney injury and direct NF-κB/AP-1 antagonism suppressing CXCL2.\",\n      \"evidence\": \"Luciferase reporters, PXR silencing/activation, proteomics, cisplatin/IR AKI rat models; Cxcl2 promoter mutagenesis and CCl4 liver injury mouse model\",\n      \"pmids\": [\"32404507\", \"33076328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PXR binding to AKR1B7 promoter vs indirect regulation not fully resolved\", \"Generality of anti-inflammatory mechanism across tissues unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the mechanism by which PXR impairs glucose metabolism, showing it suppresses HNF4α recruitment to the GLUT2 promoter, completing a metabolic regulatory picture.\",\n      \"evidence\": \"PXR overexpression/silencing in hepatocytes, ChIP for HNF4α at Slc2a2, reporter assays, liver-specific Hnf4α-KO mice, glucose tolerance tests\",\n      \"pmids\": [\"35646519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PXR directly represses HNF4α or competes for cofactors unresolved\", \"Integration with insulin signaling pathway not fully mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse ligand inputs, coregulator balance, and post-translational modification switch are integrated to select among detoxification, metabolic, anti-inflammatory, and tissue-protective transcriptional programs in a tissue-specific manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of program selection across tissues\", \"Genome-wide direct target catalog not consolidated\", \"Functional consequences of splice isoforms largely uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 3, 13, 18, 23]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 7, 9, 19]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [17, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13, 15, 21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13, 20, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [0, 2, 4, 5]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 13, 18]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 18, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 19, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 13]}\n    ],\n    \"complexes\": [\"NR1I2-RXR heterodimer\", \"HDAC3/SMRT corepressor complex\"],\n    \"partners\": [\"RXR\", \"NCOR1\", \"SMRT\", \"SRC1\", \"PPARGC1A\", \"SIRT1\", \"HDAC3\", \"TP53\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}